-
Chelsea Therapeutics Advances Neurogenic Orthostatic Hypotension Registration Program
11 Feb 2010 02:16 GMT
… 10, 2010 (FinancialWire) — Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) announced … .d. to achieve maximum therapeutic benefit.</p>
… ;#8220;Northera demonstrated broad symptomatic benefit in the treatment of neurogenic …
-
Chelsea Therapeutics OK’d To Change Droxidopa Pivotal Study 301
17 Dec 2009 06:14 GMT
… 16, 2009 (FinancialWire) — Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) said … global assessment of the clinical benefit of Droxidopa for the treatment … provide valuable information about the benefits of Droxidopa. Both the safety …
-
Chelsea Therapeutics Reports Significant Benefits Of Droxidopa Therapy
16 Dec 2009 21:14 GMT
… 16, 2009 (FinancialWire) — Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) announced … resulted in a highly significant benefit as measured by both the …
-
Chelsea Therapeutics Study Shows Symptomatic Benefits
25 Sep 2009 22:16 GMT
… , 2009 (FinancialWire) — Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) announced … supportive of the therapeutic benefit of Droxidopa in neurogenic … Patients demonstrating both a symptomatic benefit and blood pressure improvement following …
-
Multiple System Atrophy Market Expected to Experience Major Growth by 2034, According to DelveInsight
20 Jun 2024 20:15 GMT
… .
DaTSCAN™ Ioflupane: GE Healthcare
Droxidopa: Chelsea Therapeutics
Multiple System Atrophy Market Drivers … offers Healthcare Consulting Services, which benefits in market analysis to accelerate …
-
Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company Announces Dr. Simon Pedder has Joined the Board
06 Jan 2022 16:11 GMT
… products that can provide tremendous benefits to patients with cancer or … of concept programs will significantly benefit from the deep development expertise … , his experience building and selling Chelsea Therapeutics will help Voltron better position …
-
Cerecor Appoints Keith Schmidt to its Board of Directors
12 Jun 2019 20:05 GMT
… the Chief Commercial Officer of Chelsea Therapeutics International Ltd. prior to its … shut-downs); potential attributes and benefits of product candidates; the expansion …
-
Cerecor Appoints Simon Pedder to its Board of Directors
09 Apr 2018 12:07 GMT
… therapy to demonstrate a symptomatic benefit in patients with neurogenic orthostatic … Biosciences, President and CEO of Chelsea Therapeutics, Vice President of Oncology Pharma … or products, potential attributes and benefits of product candidates, the expansion …
About
© 1995-2024